Completed PHASE3 INTERVENTIONAL 2-arm NCT01063179

Velcade, Melphalan, Prednisone And Thalidomide Versus Velcade, Melphalan, Prednisone in Multiple Myeloma Patients

A PHASE III, MULTI-CENTER, RANDOMIZED OPEN LABEL STUDY OF VELCADE, MELPHALAN, PREDNISONE AND THALIDOMIDE (V-MPT) Versus VELCADE, MELPHALAN, PREDNISONE (V-MP) IN ELDERLY UNTREATED MULTIPLE MYELOMA PATIENTS

Sponsor: Fondazione EMN Italy Onlus

Conditions Multiple Myeloma

Interventions Bortezomib, Melphalan, Prednisone Bortezomib, Melphalan, Prednisone, Thalidomide

Updated 7 times since 2017 Last updated: Jun 28, 2023 Started: May 31, 2006 Primary completion: Jul 31, 2014 Completion: Jul 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Multiple Myeloma and is currently completed. Fondazione EMN Italy Onlus leads this study, which shows 7 recorded versions since 2006 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jul 2023 — Jul 2024 [monthly]

Completed PHASE3
Feb 2021 — Jul 2023 [monthly]

Completed PHASE3
Jan 2021 — Feb 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

May 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fondazione EMN Italy Onlus

Data source: Fondazione EMN Italy Onlus

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Torino, Italy